Navigation Links
Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
Date:10/28/2010

NEW YORK, Oct. 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV™ (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.  At study end point, patients receiving INTUNIV coadministered with a stimulant had significantly reduced symptoms on the ADHD Rating Scale IV (ADHD-RS-IV) compared with those receiving placebo with a stimulant, regardless of morning or evening dosing.  These data were presented in a poster session at a major national scientific meeting of psychiatry in New York, NY.

"This study looked at patients who were taking a stable dose of a long-acting stimulant medicine but who continued to experience ADHD symptoms," said Timothy Wilens, MD, Staff in the Pediatric Psychopharmacology Unit at Massachusetts General Hospital and Associate Professor of Psychiatry at Harvard Medical School, who led the study.  "These findings provide greater insight into the use of INTUNIV when combined with a stimulant."

INTUNIV is a selective alpha-2A agonist approved for the treatment of ADHD in children and adolescents ages 6 to 17.  Efficacy was based on two pivotal studies (8 and 9 weeks in duration) of INTUNIV administered as monotherapy.  INTUNIV is indicated as an integral part of a total treatment program that may include counseling or other measures.

These data presented today were included as part of a supplemental New Drug Application (sNDA) submitted to the Food and Drug Administration (FDA) on April 28, 2010, seeking approval for INTUNIV as an ADHD
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
2. Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreichs Ataxia
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
5. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
8. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
9. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
10. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... ... office , ... Ill. (Vocus) December 9, 2009 -- As part of ongoing efforts to expand deployment ... in the contaminated soil , sediment and groundwater remediation industry, is ...
... , , WALTHAM, Mass., Dec. 8 ... Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... at 8:30 a.m. EST, to discuss results of its Phase 3 ... , This call is being webcast by Thomson/CCBN and can ...
... , CLEVELAND, ... high-performance products to the market with a Smart ... performance and recyclable packaging, Nutek,s products continue to ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091208/CL22934 ) ...
Cached Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3Nutek, LLC Introduces New Soy-Based, Biodegradable Lubricating and Cleaning Wipes 2
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
(Date:10/14/2014)... MA – A team of scientists led by ... (UMMS) and the University of Miami Miller School ... a key genetic pathway underlying bipolar (manic depressive) ... drugs for treating bipolar affective disorder, as well ... The new findings, published online this week in ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... Now, a St. Louis-area teenage boy and a computer ... conducted by a team of neurosurgeons, neurologists, and engineers ... boy, a 14-year-old who suffers from epilepsy, is the ... Invaders, using only the signals from his brain to ...
... In a study appearing in the forthcoming issue of ... Tyre, and Svata M. Louda (all of the University ... aren't all eaten at the same rate. , ... the nutritional quality or defective chemistry of plant tissues. ...
... speed healing at sites of injury - such as heart ... stroke - doctors would like to be able to hasten ... to "mobilize" patients' blood vessel-forming cells, called angiogenic cells, so ... at Washington University School of Medicine in St. Louis demonstrated ...
Cached Biology News:Teenager moves video icons just by imagination 2Teenager moves video icons just by imagination 3Drug can quickly mobilize an army of cells to repair injury 2